0000899243-17-021477.txt : 20170905
0000899243-17-021477.hdr.sgml : 20170905
20170905183345
ACCESSION NUMBER: 0000899243-17-021477
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170831
FILED AS OF DATE: 20170905
DATE AS OF CHANGE: 20170905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novak Rodger
CENTRAL INDEX KEY: 0001682017
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 171069857
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-08-31
0
0001674416
CRISPR Therapeutics AG
CRSP
0001682017
Novak Rodger
C/O CRISPR THERAPEUTICS AG
BAARERSTRASSE 14
6300 ZUG
V8
SWITZERLAND
1
1
0
0
Chief Executive Officer
Common Shares
2017-08-31
4
S
0
14617
20.8711
D
1148007
D
Common Shares
2017-09-05
4
M
0
3853
1.81
A
1151860
D
Common Shares
2017-09-05
4
S
0
3853
20.3271
D
1148007
D
Stock Options (Right to Buy)
1.81
2017-09-05
4
M
0
3853
0.00
D
2025-09-10
Common Shares
3853
40826
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.46 to $21.26, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.60, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter.
/s/ Michael Esposito, attorney-in-fact
2017-09-05